Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Completed
Fred Hutchinson Cancer Research Center
Phase 2
2007-04-01
RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host
disease in patients undergoing a stem cell transplant for hematologic cancer.
PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate
works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell
transplant for hematologic cancer.
Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia
Completed
IWK Health Centre
N/A
2001-07-27
While many short-term morbidities associated with extreme prematurity have declined over the
last two decades, the incidence of bronchopulmonary dysplasia (BPD) has increased to a rate
of approximately 45% in neonates
Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia
Completed
Sunnybrook Health Sciences Centre
N/A
2001-07-27
While many short-term morbidities associated with extreme prematurity have declined over the
last two decades, the incidence of bronchopulmonary dysplasia (BPD) has increased to a rate
of approximately 45% in neonates
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: May 24, 2026
BECLOVENT clinical trials update, market analysis, and projection (2026–2035)
No complete, decision-grade dataset is available to produce an accurate clinical-trials update, market sizing, or forecast for “BECLOVENT” (drug identity, active ingredient, regulatory status, trial identifiers, sponsor/phase, geography, and sales base year are not verifiably specified).
What is BECLOVENT’s active ingredient and FDA/EMA status?
No verifiable mapping from “BECLOVENT” to a specific marketed drug, active ingredient, or approved brand in major regulators can be produced from the provided information.
Without that mapping, the Orange Book / EU register status, exclusivity, and approval pathway cannot be tied to a concrete product profile.
Which clinical trials are ongoing for BECLOVENT, and what phases are they in?
Clinical-trials update requires at minimum: NCT/EudraCT identifiers, phase, indication, sponsor, enrollment, start date, primary endpoint, and latest posted status.
No such trial identifiers or sponsor/phase data are available in the prompt, so no authoritative “latest status” can be compiled.
What were the most recent efficacy and safety readouts for BECLOVENT?
Readouts must be grounded in posted results, publications, conference abstracts, or regulatory submissions with date-stamped efficacy/safety outcomes.
No efficacy/safety dataset is available here, so no credible summary can be produced.
When does BECLOVENT’s next trial milestone occur, and how does that drive valuation?
Milestone-based projections depend on trial timelines and regulatory milestones (PDUFA, CHMP opinion dates, BLA/NDA dates).
No milestone calendar is available for “BECLOVENT.”
What is the current competitive landscape for BECLOVENT’s indication?
Competitive landscape requires: indication, line of therapy, mechanism of action, route/dose, and the local market’s existing standard of care.
Without the indication and MOA, no defensible competitor set or positioning can be stated.
How big is the BECLOVENT market opportunity by geography and patient segment?
Market projection requires: global and country-level incidence/prevalence, treated population, existing therapy shares, pricing assumptions, and reimbursement dynamics.
None of these inputs can be connected to a specific “BECLOVENT” product from the prompt.
What revenue projection scenarios apply to BECLOVENT (base, upside, downside)?
Scenario forecasts require anchored assumptions: net price, time-to-peak, uptake curve, persistence, physician adoption, payer restrictions, and manufacturing capacity.
Those assumptions cannot be tied to the correct drug profile.
What regulatory strategy affects BECLOVENT uptake (priority review, Fast Track, accelerated approval)?
These require documented FDA/EMA designations and pathway status tied to a specific BLA/NDA and indication.
No regulatory pathway data is available.
What patent and exclusivity constraints could delay generic or biosimilar entry for BECLOVENT?
Patent constraints require Orange Book or EP register listings, patent numbers, listed expiration dates, and exclusivity terms.
“BECLOVENT” identity is not specified with enough information to retrieve and analyze patent estates.
What generic entry risks exist for products that compete with BECLOVENT?
Generic risk depends on exclusivity and patent challenge history (e.g., Paragraph IV filings), which cannot be analyzed without product mapping.
No challenge history is available for the prompt.
Key Takeaways
A complete and accurate clinical-trials update, market analysis, and revenue projection for “BECLOVENT” cannot be produced because the drug’s active ingredient, regulatory identity, trial identifiers, and performance data are not specified in the input.
FAQs
How do I identify BECLOVENT’s active ingredient to check Orange Book listings?
What trial registries should be searched first to build an auditable clinical-trials update?
How are time-to-peak and uptake curves typically modeled for small-molecule brands?
How do patent cliffs and exclusivity windows change NPV and launch timing?
What market sizing method is used when no robust sales history exists for a new entrant?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
